| Aspire Mining Limited (AKM) ORDINARY FULLY PAID |
Materials |
$119 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
31 Jan 2025 11:25AM |
$0.240 |
$0.235 |
fallen by
2.08%
|
|
AKM - Price-sensitive ASX Announcement
Full Release
Key Points
- Focus on Ovoot Coking Coal Project development.
- Tenders issued for coal handling and preparation plant construction.
- Detailed engineering design for Ovoot camp is underway.
- Management visited potential customers in northern China.
- Bulk coal samples prepared for marketing to potential customers.
- Engaged with Public-Private Partnership Agency for road infrastructure project.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Tolu Minerals Limited (TOK) ORDINARY FULLY PAID |
Materials |
$123 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
31 Jan 2025 11:22AM |
$0.880 |
$0.835 |
fallen by
5.11%
|
|
TOK - Price-sensitive ASX Announcement
Full Release
Key Points
- Commenced commissioning of modular gravity production circuit.
- Appointment of Chris Muller as Executive Group Geologist.
- Completion of six holes in surface drilling program.
- Significant progress on airborne magneto telluric survey analysis.
- Refurbishment of mine camp and process plant underway.
- Initiated environmentally sustainable tailings management plan.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Peter Warren Automotive Holdings Limited (PWR) ORDINARY FULLY PAID |
Consumer Discretionary |
$252 |
Notice of H1 FY25 Result and Conference call
|
31 Jan 2025 11:22AM |
$1.555 |
$1.465 |
fallen by
5.79%
|
|
| Renu Energy Limited (RNE) ORDINARY FULLY PAID |
Utilities |
$0 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 Jan 2025 11:21AM |
$0.001 |
$0.001 |
fallen by
0%
|
|
| Kinetiko Energy Limited (KKO) ORDINARY FULLY PAID |
Energy |
$72 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
31 Jan 2025 11:20AM |
$0.059 |
$0.050 |
fallen by
15.25%
|
|
KKO - Price-sensitive ASX Announcement
Full Release
Key Points
- Kinetiko Energy Limited is focused on developing gas resources in South Africa.
- The company commenced a five-well gas production test program to assess its reserves.
- The first well, ER 271-23PT, was completed but did not produce commercial gas quantities.
- The company is optimistic about the remaining wells due to their strategic positioning near key infrastructure.
- Kinetiko has approximately $2.28 million in available funds with no debt.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Thunderbird Resources Limited (THB) ORDINARY FULLY PAID |
Materials |
$4 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
31 Jan 2025 11:16AM |
$0.019 |
$0.010 |
fallen by
47.37%
|
|
THB - Price-sensitive ASX Announcement
Full Release
Key Points
- Thunderbird Resources acquired Kookabookra and Rockvale projects.
- Total exploration expenditure for the quarter was $1,363k.
- Picha Project selected for BHP Xplor's 2025 accelerator program.
- George Ventouras appointed as new Executive Chairman.
- Company plans to mobilize exploration teams in 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$8 |
Proposed issue of securities - HIQ
|
31 Jan 2025 11:14AM |
$0.047 |
$0.021 |
fallen by
55.32%
|
|
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$8 |
Noteholder to Convert $1.6m of Notes, Issue of Shares
|
31 Jan 2025 11:14AM |
$0.047 |
$0.021 |
fallen by
55.32%
|
|
HIQ - Price-sensitive ASX Announcement
Full Release
Key Points
- No Bull Health Pty Ltd intends to convert a $1.6 million Convertible Note.
- Conversion price is at a 10% discount to the VWAP of HITIQ shares.
- The conversion was discussed in a Board meeting on 8 October 2024.
- Harmil agreed to a post discount conversion price of $0.020.
- HITIQ will issue shares to external service providers totaling $161,807.
- HITIQ has entered a revised Corporate Advisory Mandate with Henslow Pty Ltd.
- Shares will be issued from the company's ASX Listing Rule 7.1 placement capacity.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Qualitas Real Estate Income Fund (QRI) ORDINARY UNITS FULLY PAID |
Financials |
$980 |
Distribution Announcement
|
31 Jan 2025 11:13AM |
$1.670 |
$1.610 |
fallen by
3.59%
|
|
| Rox Resources Limited (RXL) ORDINARY FULLY PAID |
Materials |
$205 |
Change in substantial holding
|
31 Jan 2025 11:13AM |
$0.215 |
$0.280 |
risen by
30.23%
|
|
| Excite Technology Services Limited (EXT) ORDINARY FULLY PAID |
Information Technology |
$21 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 Jan 2025 11:10AM |
$0.010 |
$0.010 |
fallen by
0%
|
|
EXT - Price-sensitive ASX Announcement
Full Release
Key Points
- Excite reaches positive EBITDA in December.
- Digital Forensics division secured contracts worth $4.06M.
- Customer receipts doubled to $4.08M compared to the previous quarter.
- Unaudited revenues increased to $5.07M from $1.06M.
- Closing cash was $810k, with $2.6M in receivables.
- CDFS acquisition is enhancing financial performance.
- Excite aims to expand in cyber, IT consulting, and DFIR markets.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Group 6 Metals Limited (G6M) ORDINARY FULLY PAID |
Materials |
$548 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
31 Jan 2025 11:10AM |
$0.025 |
$0.025 |
fallen by
0%
|
|
| Qualitas Real Estate Income Fund (QRI) ORDINARY UNITS FULLY PAID |
Financials |
$980 |
Dividend/Distribution - QRI
|
31 Jan 2025 11:09AM |
$1.670 |
$1.610 |
fallen by
3.59%
|
|
| Investa Office Fund (IOF) ORDINARY FULLY PAID |
Real Estate |
- |
mFund - Fund Profile - IOF01
|
31 Jan 2025 11:09AM |
$5.580 |
$5.580 |
fallen by
0%
|
|
| eInvest Better Future (Managed Fund) (IMPQ) |
Financials |
$45 |
IMPQ Monthly Portfolio Disclosure
|
31 Jan 2025 11:06AM |
$5.060 |
$4.830 |
fallen by
4.55%
|
|
| Perennial Income Generator Fund (Managed Fund) (EIGA) |
Financials |
$32 |
EIGA Monthly Portfolio Disclosure
|
31 Jan 2025 11:04AM |
$3.870 |
$3.890 |
risen by
0.52%
|
|
| Audio Pixel Holdings Limited (AKP) ORDINARY FULLY PAID |
Consumer Discretionary |
$181 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 Jan 2025 11:03AM |
$6.200 |
$6.200 |
fallen by
0%
|
|
| Asian Masters Fund Limited (AUF) ORDINARY FULLY PAID |
Financials |
- |
mFund - Fund Profile - AUF01
|
31 Jan 2025 11:03AM |
$1.280 |
$1.280 |
fallen by
0%
|
|
| Chimeric Therapeutics Limited (CHM) ORDINARY FULLY PAID |
Health Care |
$8 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 Jan 2025 11:00AM |
$0.006 |
$0.004 |
fallen by
33.33%
|
|
CHM - Price-sensitive ASX Announcement
Full Release
Key Points
- First three patients dosed in Phase 1/2 clinical trial of CHM CDH17 CAR-T cell therapy.
- Phase 1B ADVENT-AML trial now including newly diagnosed AML patients.
- Complete response reported in an AML patient 28 days after treatment in CHM CORE-NK trial.
- $5 million raised through a two-tranche placement for ongoing programs.
- Dr. Rebecca McQualter appointed as CEO.
- Received $4.17 million R&D tax incentive under Australian Government's scheme.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Goodman Fielder Limited (GFF) ORDINARY FULLY PAID |
Consumer Staple |
- |
mFund - Fund Profile - GFF01
|
31 Jan 2025 10:58AM |
$0.670 |
$0.670 |
fallen by
0%
|
|
| Vectus Biosystems Limited (VBS) ORDINARY FULLY PAID |
Health Care |
$3 |
Quarterly Activities & Appendix 4C Cash Flow Reports
|
31 Jan 2025 10:58AM |
$0.079 |
$0.048 |
fallen by
39.24%
|
|
VBS - Price-sensitive ASX Announcement
Full Release
Key Points
- Vectus Biosystems Limited is focused on developing treatments for fibrosis.
- The company successfully completed its Initial Public Offering on ASX in February 2016.
- VB0004 aims to treat hardening of functional tissue and high blood pressure.
- The Phase Ia/Ib clinical trial has been finalized with results expected in early 2025.
- The company reduced operating costs while focusing on potential licensing opportunities.
- Vectus concluded the quarter with $810,000 in cash after an R&D tax refund.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Dotz Nano Limited (DTZ) ORDINARY FULLY PAID |
Information Technology |
$27 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 Jan 2025 10:57AM |
$0.085 |
$0.045 |
fallen by
47.06%
|
|
DTZ - Price-sensitive ASX Announcement
Full Release
Key Points
- Received first commercial order for DotzShield from a leading energy solutions provider.
- Demonstrated high adsorption capacity and low energy usage for Direct Air Capture.
- Signed collaboration agreement with Bar-Ilan University for electrochemical DAC technology pilot.
- U.S. institutional shareholder invested A$2 million to support DotzEarth development.
- Focused on advancing carbon management technologies for a sustainable future.
- 2025 objectives include scaling-up sorbent production and further commercializing DotzShield.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| AMP Capital China Growth Fund (AGF) ORDINARY FULLY PAID |
Financials |
- |
mFund - Fund Profile - AGF01
|
31 Jan 2025 10:57AM |
$0.360 |
$0.360 |
fallen by
0%
|
|
| Arovella Therapeutics Limited (ALA) ORDINARY FULLY PAID |
Health Care |
$98 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 Jan 2025 10:57AM |
$0.190 |
$0.083 |
fallen by
56.32%
|
|
ALA - Price-sensitive ASX Announcement
Full Release
Key Points
- Cash and cash equivalents position as at 31 December of $11.8 million
- Clinical Advisory Board established in preparation for FDA IND application
- Key milestones anticipated in 2025 for ALA-101
- Firm commitments received for a $20 million Placement at $0.17 per share
- Arovella fully funded to complete Phase 1 with $20 million placement
- The funding will also support the advancement of the company’s solid tumour programs
- R&D tax rebate of $3.3 million received
- G-Rex® grant funding received for optimizing clinical manufacturing process
- Investor relations activities included presentations at major conferences
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Structural Monitoring Systems Plc (SMN) CHESS DEPOSITARY INTERESTS 1:1 |
Information Technology |
$63 |
Quarterly Activities Report & Appendix 4C
|
31 Jan 2025 10:57AM |
$0.485 |
$0.405 |
fallen by
16.49%
|
|
SMN - Price-sensitive ASX Announcement
Full Release
Key Points
- Cash balance as of 31 December 2024 was $7.09 million.
- Total cash inflow from operating activities was $7.28 million.
- Net cash used in operating activities was $127,000.
- Payments for product manufacturing and operating costs totaled $2.73 million.
- Staff costs incurred were $3.41 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Goals & planningInvesting goal hubsSaving to build wealth
Saving for happy retirement 
Call 1300 880 160
Start a chat
Schedule a call
